EVALUATION OF IMMUNE RESPONSE AGAINST REDUCED DOSE OF Brucella abortus STRAIN 19 VACCINE ADMINISTERED THROUGH CONJUNCTIVAL ROUTE IN CATTLE

Chaithra Y1, Isloor S1*, Shivaram B2, Suryaprasad V2, Sharada R1, Rathnamma D1, Srinivas K2, Veeregowda BM1, Narayanaswamy HD3, Shome BR4, Kundan SP2

1Department of Microbiology, Veterinary college, KVAFSU, Hebbal, Bangalore-560 024
2Indian Immunologicals Ltd., Gachibowli, Hyderabad-500 032
3Hon’ble Vice Chancellor, KVAFSU, Bidar-585401
4ICAR-National Institute of Veterinary Epidemiology and Disease Informatics, Ramagondanahalli, Yelahanka, Bangalore-560 064

Received – December 03, 2017; Revision – February 09, 2018; Accepted – June 30, 2018
Available Online – August 10, 2018

DOI: http://dx.doi.org/10.18006/2018.6(4).739.745

KEYWORDS
Brucellosis
Conjunctival vaccine
Immune response
Cattle

ABSTRACT

A study was undertaken to evaluate the immune response against Brucella abortus S19 reduced dose vaccine administered through conjunctival route in comparison with B. abortus S19 standard dose administered through subcutaneous (S/C) route. All, 38 Brucella seronegative cattles were grouped as Group 1 with 24 animals (>8 months), Group 2 with 8 female calves (4-8 months), Group 3 with 6 animals (>8 months). On day 0, Group 1, 2 and 3 animals were administered with reduced dose (5-8×10^9 CFU/dose) vaccine through conjunctival route, standard dose (40-80×10^9 CFU/dose) vaccine through S/C route and normal saline through conjunctival route respectively. Blood and serum samples were collected on 0, 21, 60, 90, 120, 150 and 180 Day of post vaccination (DPV). On 120th day, Group 1 animals received booster conjunctival vaccine dose (5-8×10^9 CFU/dose). The humoral and cell mediated immune (CMI) response induced by conjunctival and S/C route vaccine was determined by Competitive Enzyme Linked Immuno Sorbant assay (C-ELISA) and Interferon-γ (IFN-γ) assay respectively. The vaccinal antibodies on 21, 60, 90, 120, 150 and 180 DPV were 33.3, 41.6, 17.3, 22.7, 77.2 and 70.1% respectively in conjunctival group and 100, 100, 87.5, 50, 33.3 and 30.2 % respectively in S/C route vaccine group. Stimulation index (>8.89) for IFN-γ response on 21, 60, 90, 120 and 180 DPV were

* Corresponding author
E-mail: kisloor@gmail.com (Dr. Shrikrishna Isloor)

Peer review under responsibility of Journal of Experimental Biology and Agricultural Sciences.
2.1 Selection of animals

Brucella seronegative cattle were selected based on Rose Bengal Plate Test (RBPT) and Competitive Enzyme Linked Immuno Sorbant Assay (C-ELISA) from the organized farm by using AHVLA kit method.

2.2 Study vaccine

Brucella abortus S19 reduced dose vaccine of $5 \times 10^9$ to $8 \times 10^9$ CFU organisms were administered through conjunctival route. A standard vaccine dose of $40 \times 10^9$ to $80 \times 10^9$ CFU viable organisms were administered through S/C route. Both the vaccines used in the present study were procured by Indian Immunological Ltd. (IIL), Hyderabad.

2.3 Experimental design

Animals were broadly grouped in three groups viz. Group 1 -3. Among these, group-1 consists 24 animals (more than eight months age irrespective of breed and stage of lactation) and had a vaccine dose of $5 \times 10^9$ to $8 \times 10^9$/CFU which was administered through conjunctival route. The booster dose was administered on 120th day. While group 2 have eight female calves (four- eight months age) those are vaccinated with dose of $40 \times 10^9$ to $80 \times 10^9$/CFU/dose was administered through S/C route. Group 3 contain only six animals (more than eight months age irrespective of breed and stage of lactation). This group was placebo group and received only normal saline through conjunctival route.
2.4 Rose Bengal Plate Test (RBPT)

Rose Bengal colored antigen was procured from the Institute of Animal Health and Veterinary Biologicals (IAH and VB), Bengaluru. The antigen comprises of *B. abortus S99* smooth 11 per cent cell suspension buffered to a low pH, usually 3.65 ± 0.05. On a clean microscopic slide, equal volume (30μl) of antigen and test serum sample were mixed thoroughly by tip of the micropipette and rotated gently for 3 min at RT. Immediately after 3 min of incubation results were recorded as positive or negative based on the presence or absence of agglutination, respectively.

2.5 Interferon-γ Release Assay

2.5.1 Sample collection and processing for IFN-γ assay

Whole blood samples were collected from jugular vein of animals using 18 gauge needle attached to a vacutainer coated with heparin (Beckton Dickinson, Cat. No. 367874), on 0, 21st, 60th, 90th, 120th, 150th and 180th day. One ml of blood sample was added in 24 well cell culture plates in pre-determined format (Nunc, Denmark, Cat. No.142475). Blood sample each in duplicate, were stimulated with heat killed antigen of *B. abortus* S19 and *B. abortus* S44 at 10µl concentration i.e. *B. abortus* S19 at 400µg /10µl and *B. abortus* S44 at 10µg / 10µl concentration of protein content diluted in PBS (pH 6.4) at 100 µl/ml of blood/well. Blood samples were also stimulated with pokeweed mitogen lectin from *Phytolacca americana* (Sigma-Aldrich, Cat. No.L9379-10MG) 8µl / ml of blood / well at concentration of 1µg / ml of distilled water and PBS 100 µl / ml of blood / well as positive and negative controls, respectively. The 24 well plates were incubated in humidifier chamber at 37°C with 5 per cent CO2 for 24 h and Plasma samples were collected after 24 h by manual pipetting and stored at -20°C till processed for standard ELISA for interferon γ.

The Sandwich ELISA was employed to detect IFN-γ derived from whole blood stimulated plasma samples. ELISA plates were coated with 1:2000 diluted monoclonal capture antibody CC330 (100µl / well) diluted in PBST and incubated overnight at 4°C. Unbound antibody washed thrice using washing buffer (PBST). Blocking buffer (200 µl / well) was added to all the wells and kept on the plate shaker (500-600) for 1h at RT and this was followed by three washing of PBST. Antigen standard was prepared ranging from 1000pg/ml to 4pg/ml and added in respective wells (100µl / well). Plasma samples were added to respective wells (100µl /well) and PBST added to the control wells (100µl / well). The plates were incubated for 1h on the plate shaker at RT and washed thrice with PBST. Biotinylated antibody was prepared at 1: 4000 dilution and added 100 µl / well. The plates were incubated at RT for 1h on the plate shaker and this was followed by the three time washing of plate with PBST. Streptavidin HRP was prepared at 1:8000 dilution and added 100 µl / well. The plates were incubated at RT for 1h on the plate shaker and the plate washed thrice with PBST. Substrate solution was prepared by dissolving one TMB tablet in 10 ml of substrate buffer followed by addition of 3 µl of 30% H2O2. The solution was added at 100µl / well and the plates were incubated at RT for 30 min on the plate shaker. After 30 min, color reaction was stopped by adding 0.18M H2SO4 at 100µl / well. Optical density of the wells was measured at 450 nm.

Cut off was taken based on the formula: Mean + 2 × SD (Standard deviation)

\[
SI = \frac{\text{Sample OD − Blank OD}}{\text{Sample PBS OD − Blank OD}}
\]

2.5.2 Competitive Enzyme Linked Immuno Sorbent Assay

Blood was collected on 0, 21st, 60th, 90th, 120th, 150th and 180th day with sterile 18 gauge needle and vacutainers (9ml, capacity) without anticoagulant and allowed to clot for 30 minutes, before transportation to laboratory on ice. The separated serum was stored at -20°C in aliquots with proper label till further use. Competitive ELISA was performed using AHVLA kit method for the collected serum samples.

3 Results

This study was undertaken to evaluate the safety and immunogenicity of *B. abortus* S19 reduced dose vaccine administered through conjunctival route in comparison with of *B. abortus* S19 standard dose vaccine administered through S/C route.

3.1 Selection of animals

Based on the result of RBPT, out of 70 studied animals, 50 seronegative animals were selected. Competitive ELISA was performed using AHVLA kit method for 50 seronegative animals which were seronegative by RBPT. Based on result of C-ELISA, we selected 38 seronegative animals out of 50 for the study.

3.2 Safety Evaluation

Safety evaluation was done by observing and recording the adverse events during the first 30 min to 1 h after vaccination. The animals were observed for local pain, swelling, rashes, skin eruption, redness at administration site, induration, fever, loss of appetite, restlessness and unsolicited systemic events etc. No serious adverse events were recorded in the study.
3.3 Evaluation of the efficacy of vaccination

3.3.1 Humoral Immune Response by C-ELISA

The humoral immune response induced by *B. abortus* S19 reduced dose conjunctival route vaccine was determined by Competitive ELISA using AHVLA kit. Below or equal to 60 per cent of conjugate control OD value was considered as positive. Above 60 per cent of conjugate control OD value was considered as negative. In reduced dose conjunctival vaccine group, the percentage of responders on 21 and 60 DPV were 33.3 and 41.6 per cent respectively. Subsequently, the percentage of responders increased to 77.2 per cent on 150 DPV after administering the booster dose (Table 1). Whereas in standard dose S/C route vaccinated group, the percentage of responders was 100 percent in both 21 and 60 DPV. Thereafter, the percentage of responders was reduced at 90, 120, 150 and 180 DPV (Table 1).

3.3.2 Cell Mediated Immune Response by IFN – gamma assay

The cell mediated immunity was determined by Interferon-γ assay with Sandwich ELISA, a useful method to reveal the presence of immune response following lymphocyte stimulation with heat killed *B. abortus* S19 and 544 (Plate 1). The interferon-γ assay results were expressed as percentage responders based on stimulation indices (SI), calculated as the ratio between the mean OD value of IFN-γ from blood cells stimulated with specific antigen at 450nm and the mean optical density values of IFN-γ from blood cells stimulated with PBS control as described by Weynants et al. (1995). Two cut-off values 8.89 and 9.26 were obtained when the blood samples were stimulated against *B. abortus* S19 and 544 respectively. The samples exhibiting above the cut off values were considered as responders for CMI.

The IFN-γ response induced by *B. abortus* S19 reduced dose conjunctival vaccine as determined by sandwich ELISA titre indicated that by 21 DPV, 25 per cent of the cattle responded to the *B. abortus* S19 heat killed antigen. After administration of booster dose on 120 DPV, percent of responders increased from 50 per cent to 69.5 per cent (Table 2). Similar findings were observed in group of animals stimulated with *B. abortus* 544 antigen (Table 3). However, almost all the animals responded for the reduced dose conjunctival route vaccine. The control group cattle remained unresponsive throughout the trial period for both the antigens.

### Table 1

<table>
<thead>
<tr>
<th>Group</th>
<th>0</th>
<th>21</th>
<th>60</th>
<th>90</th>
<th>120</th>
<th>150</th>
<th>180</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conjunctival</td>
<td>33.3</td>
<td>41.6</td>
<td>17.3</td>
<td>22.7</td>
<td>77.2</td>
<td>70.1</td>
<td></td>
</tr>
<tr>
<td>Subcutaneous</td>
<td>100</td>
<td>100</td>
<td>87.5</td>
<td>50</td>
<td>33.3</td>
<td>30.2</td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

### Table 2

<table>
<thead>
<tr>
<th>Group</th>
<th>0</th>
<th>21</th>
<th>60</th>
<th>90</th>
<th>120</th>
<th>150</th>
<th>180</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conjunctival</td>
<td>25</td>
<td>70.8</td>
<td>52.1</td>
<td>50</td>
<td>69.5</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>Subcutaneous</td>
<td>37.5</td>
<td>37.5</td>
<td>25</td>
<td>50</td>
<td>33.3</td>
<td>16.7</td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

### Table 3

<table>
<thead>
<tr>
<th>Group</th>
<th>0</th>
<th>21</th>
<th>60</th>
<th>90</th>
<th>120</th>
<th>150</th>
<th>180</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conjunctival</td>
<td>41.6</td>
<td>62.5</td>
<td>52</td>
<td>45</td>
<td>52</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>Subcutaneous</td>
<td>50</td>
<td>37.5</td>
<td>25</td>
<td>50</td>
<td>33.3</td>
<td>16.7</td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

4 Discussion

As control of bovine brucellosis is concerned, currently, *B. abortus* S19 vaccine is being used in most of the countries in female calves in the age group of 4-8 months. Serological evidence suggested that brucellosis is endemic in most parts of India (Isloor et al., 1998; Renukaradhya et al., 2002; Khurana et
In the present study, seronegative cattle (n=50) as detected by RBPT in an organized farm were selected. Further, C-ELISA, detected only 38 out of 50 RBPT negative serum samples to be negative. The C-ELISA being more sensitive than RBPT identified 12 out of 50 RBPT based seronegatives to be *brucella* positive. In view of this, all the 38 RBPT and C-ELISA based *brucella* seronegative samples were included in the study. Guarrino et al. (2001) found that ELISA was more effective in detection of infection than RBPT because sensitivity of ELISA is higher than RBPT. Animals of the age >8 months and 4-8 months were selected for conjunctival and S/C vaccine respectively.

4.1 Cell Mediated Immune Response by IFN-γ assay

Protective immunity against brucellosis involves both humoral and CMI responses (Nicoletti, 1990). Lymphocyte proliferation and cytokine detection assays are the most widely used correlates of CMI responses. A useful method to reveal the presence of CMI response against *B. abortus* can be the detection of Interferon-γ production following lymphocyte stimulation with the specific antigen. The test utilizes, *in vitro*, the same mechanism that can be evoked *in vivo* by the brucellin skin test. Previous studies conducted on this topic demonstrated that *Brucella* species is able to elicit a macrophage response through the production of IFN-γ by stimulated T lymphocytes both in mice (Jones & Winter, 1992) and in cattle infected with *B. abortus* (Weynants et al., 1995).

The CMI response against *B. abortus* S19 and S44 studied by IFN-γ assay revealed a good response in the group of animals where reduced dose vaccine was used. The IFN-γ response was comparatively high on 60 DPV in reduced dose conjunctival route group animals in comparison with the animals in the standard dose S/C route group indicating good CMI response which is pivotal in controlling and eliminating intracellular pathogens like *Brucella*. From 60 to 120 DPV (Table 2 & 3), the percentage responders drastically reduced. None of the control animals were reported positive. Odibileg et al. (2008) observed increased level of IFN-γ during 1st week and reduced level of IFN-γ on 2nd and 3rd week after vaccination with *B. abortus* S19 reduced dose S/C route vaccine. However, titres increased on 150 DPV due to the administration of booster on 120 DPV. Interferon-γ response against heat killed *B. abortus* S44 also showed similar results as that of IFN-γ response against heat killed *B. abortus* S19 antigen.

Conjunctival administration of live vaccines was shown to induce good IFN-γ response but low serological responses (Plommet & Fensterbank, 1976; Plommet & Fensterbank, 1979; Fensterbank et al., 1985; Fensterbank et al., 1987).

4.2 Humoral Immune Response by C-ELISA

The humoral immune response induced by *B. abortus* S19 reduced dose conjunctival route vaccine was determined by Competitive ELISA using AHVLA kit. The humoral immune response of conjunctival vaccine was comparable with that of standard dose vaccine after booster dose at the end of the study indicating the good response to booster dose. Plommet & Fensterbank (1976) demonstrated that vaccination of adult animals with reduced dose of S19 vaccine by conjunctival route did not induce persistent antibody titers, and the level of protection achieved was comparable to that of a standard dose given by S/C route. In humoral immune response, *B. abortus* S19 standard dose S/C route vaccine group revealed higher percentage of responders. It was 100 per cent for both 21 and 60DPV. After 60DPV, the percentage of responders drastically reduced. Whereas, *B. abortus* S19 reduced dose conjunctival route vaccine drastically increased the percentage of responders on 150 DPV after inoculation of the booster dose on 120 DPV. The control cattle remained unresponsive throughout the study period (Table 1). In this study, the vaccination by S/C route with standard dose produced 100 percent seroconversion. In the low dose conjunctival vaccine group, there was less seroconversion and even after booster 100 percent seroconversion was not noticed. This could be attributed to vaccine strain colonization mostly restricted to the lymph nodes of the head in case of conjunctival vaccination (Plommet & Fensterbank, 1976), whereas, S/C vaccination systemically extends colonization to other lymphoid organs including spleen; hence a higher serological response.

Chand et al. (2014) suggested that the problem of persistent antibody titers due to subcutaneous vaccination of adult animals could be circumvented if conjunctival route is used for vaccination. Further, it was reported that vaccination of adult animals with a low dose *B. abortus* S19 vaccine by conjunctival route did not result in either abortion or persistancy of vaccinal antibodies, which are the major limitations in case of subcutaneously vaccinated adult animals. Furthermore, the findings of this study were in concurrence with Poster et al. (2002), who also recorded that the animals vaccinated with a reduced conjunctival dose were found to be free from detectable antibodies in less than three months post vaccination. These rapid decrease in the antibody suggested that this practice could be adopted in the campaign against brucellosis.

Conclusion

The *B. abortus* S19 reduced dose vaccine is safe and effective in female cattle above 8 months of age when administered through
conjunctival route. The safety and immunogenicity study of B. abortus S19 reduced dose conjunctival route vaccine in cattle revealed that it was safe after conjunctival administration without any local or systemic adverse events for a period of 180 days and effective in eliciting a good CMI and humoral immune response which was comparable to that of standard dose vaccine. In a country like India, where there is a ban on test and slaughter programme, in such condition vaccination serves as the only means of disease control which will reduce the numbers of positive reactors in a herd and is directly related to the percentage of vaccinated animals. However, as for the B. abortus S19 vaccination is concerned, the age restrictions are imposed because the serological response to immunization is less prolonged in young animals and takes time to disappear before they grow old enough to need testing. The agglutinin titres following administration of B. abortus S19 vaccine cannot be distinguished from those that result after infection; a major disadvantage of B. abortus S19 vaccine particularly in calves vaccinated after the eighth month. But, circumstances arise when immunization of adult cattle may be advisable and these necessitate the use of reduced doses of B. abortus S19. Keeping the above in view, and as per the report of World Organization for Animal Health (OIE)-2013, reduced CFU levels per dose of vaccine could be administered through the conjunctival route in adult cattle to overcome the afore mentioned drawbacks. This approach could be highly useful in controlling bovine brucellosis in areas where brucellosis is endemic.

Conflict of Interest

The authors declare that there is no conflict of interest regarding the publication of this review paper.

References


OIE (World Organisation for Animal Health) 2016. Bovine brucellosis. Section 2.4.3.


The authors declare that there is no conflict of interest regarding the publication of this review paper.
conjunctival route. iv. Comparison between two methods of vaccination. Annales de recherches veterinaries 10: 131-139


